Abstract
TACI is a member of the tumor necrosis factor receptor superfamily and serves as a key regulator of B cell function. The extracellular domain of a typical TNFR contains multiple copies of CRD, which bind in the monomermonomer interfaces of a trimeric ligand. TACI binds to two ligands, APRIL and BAFF, with high affinity and contains two CRD in its extracellular regions, while BCMA and BR3, contain a single or partial CRD for binding the two ligands. However, TACI can be classified as a single CRD receptor because the amino-terminal CRD1 doesnt contribute to ligand binding. To obtain a new variant of TACI possessing higher affinities for binding, we fused a repeat sequence of CRD2 to the N-terminus of the short form of TACI. The new APRIL antagonist peptide, CRD2-shortTACI-Fc, was designed based on the modeling 3-D complex structure of TACI and APRIL. As expected, the purified recombinant CRD2-shortTACI-Fc fusion protein could bind to APRIL in vitro and demonstrated dose-dependent inhibition of APRIL-induced proliferative activity in Raji cells. We found that CRD2-shortTACI-Fc, has a higher affinity for binding to ligands than short-TACI-Fc, which contains a single CRD2.
Keywords: TACI, CRD2, BAFF, APRIL, affinity, autoimmune disorders, Novagen, DNA ligase, homology modeling, Pichia pastoris
Protein & Peptide Letters
Title: Expression and Characterization of a Variant of TACI (CRD2-shortTACIFc) in Pichia pastoris
Volume: 19 Issue: 3
Author(s): Rui Wang, Shiliang Zhou, Xiaomin Peng, Xin-Wen Zhou, Zhi-Qun Xie, Yuxiong Wang, Wei Mo and Min Yu
Affiliation:
Keywords: TACI, CRD2, BAFF, APRIL, affinity, autoimmune disorders, Novagen, DNA ligase, homology modeling, Pichia pastoris
Abstract: TACI is a member of the tumor necrosis factor receptor superfamily and serves as a key regulator of B cell function. The extracellular domain of a typical TNFR contains multiple copies of CRD, which bind in the monomermonomer interfaces of a trimeric ligand. TACI binds to two ligands, APRIL and BAFF, with high affinity and contains two CRD in its extracellular regions, while BCMA and BR3, contain a single or partial CRD for binding the two ligands. However, TACI can be classified as a single CRD receptor because the amino-terminal CRD1 doesnt contribute to ligand binding. To obtain a new variant of TACI possessing higher affinities for binding, we fused a repeat sequence of CRD2 to the N-terminus of the short form of TACI. The new APRIL antagonist peptide, CRD2-shortTACI-Fc, was designed based on the modeling 3-D complex structure of TACI and APRIL. As expected, the purified recombinant CRD2-shortTACI-Fc fusion protein could bind to APRIL in vitro and demonstrated dose-dependent inhibition of APRIL-induced proliferative activity in Raji cells. We found that CRD2-shortTACI-Fc, has a higher affinity for binding to ligands than short-TACI-Fc, which contains a single CRD2.
Export Options
About this article
Cite this article as:
Wang Rui, Zhou Shiliang, Peng Xiaomin, Zhou Xin-Wen, Xie Zhi-Qun, Wang Yuxiong, Mo Wei and Yu Min, Expression and Characterization of a Variant of TACI (CRD2-shortTACIFc) in Pichia pastoris, Protein & Peptide Letters 2012; 19 (3) . https://dx.doi.org/10.2174/092986612799363136
DOI https://dx.doi.org/10.2174/092986612799363136 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
Call for Papers in Thematic Issues
Therapeutic Proteins and Peptides of Plant Origin
Plants are still the major repository of biologically active substances. In the last two decades, however, natural peptides and proteins of plant origin have gained increasing attention due to their pharmacological activities over a variety of human illnesses, including those mediated by infections and parasitosis and those involving different cellular ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multistep Renal Carcinogenesis in the Eker (Tsc 2 Gene Mutant) Rat Model
Current Molecular Medicine Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Bitter Gourd (Momordica charantia) is a Cornucopia of Health: A Review of its Credited Antidiabetic, Anti-HIV, and Antitumor Properties
Current Molecular Medicine The Wnt Pathway: Emerging Anticancer Strategies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vertebrate Protein CTCF and its Multiple Roles in a Large-Scale Regulation of Genome Activity
Current Genomics DNA Damage and Epigenetic Changes in Kidney Diseases - Focused on Transcription Factors in Podocytes
Current Hypertension Reviews Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients
Current Cancer Drug Targets Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science Engineered Exosomes for Drug Delivery in Cancer Therapy: A Promising Approach and Application
Current Drug Delivery Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer
Mini-Reviews in Medicinal Chemistry Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Induced Stem Cells as a Novel Multiple Sclerosis Therapy
Current Stem Cell Research & Therapy A Conceptual View on Glucocorticoid-Induced Apoptosis, Cell Cycle Arrest and Glucocorticoid Resistance in Lymphoblastic Leukemia
Current Molecular Medicine Meet Our Associate Editor
MicroRNA Cancer Stem Cell Niche in Colorectal Cancer and Targeted Therapies
Current Pharmaceutical Design Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects
Current Pharmaceutical Design Immunomodulatory Role of Arsenic in Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Current Pharmaceutical Design Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Current Medicinal Chemistry Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals
Current Pharmaceutical Design